Quick Answer
Anixa Biosciences Inc reported Total Revenue of $210.0 thousand for fiscal year 2023.
Anixa Biosciences Inc — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | $210.0K | — | $512.0K | — |
| Revenue (ASC 606) | — | — | $210.0K | — | $512.0K | — |
| Net Income | -$10.93M +13.0% |
-$12.55M -28.0% |
-$9.81M +27.8% |
-$13.60M -4.9% |
-$12.95M -29.3% |
-$10.02M +14.0% |
| Diluted EPS | -$0.34 +12.8% |
-$0.39 -21.9% |
-$0.32 -171.1% |
$0.45 | — | — |
| Total Assets | $16.08M -25.5% |
$21.59M -15.4% |
$25.52M -16.1% |
$30.41M -16.1% |
$36.26M +283.6% |
$9.45M +50.2% |
| Cash and Equivalents | $1.24M -2.1% |
$1.27M +38.9% |
$915.0K -92.6% |
$12.36M -57.6% |
$29.13M +353.9% |
$6.42M +83.8% |
| Stockholders Equity | $15.16M -24.2% |
$20.00M -17.8% |
$24.34M -16.2% |
$29.05M -18.0% |
$35.44M +304.5% |
$8.76M +67.3% |
| R&D Expense | $5.07M -20.7% |
$6.40M +34.1% |
$4.77M -28.9% |
$6.70M +8.3% |
$6.19M +41.3% |
$4.38M -20.0% |
| Operating Income | -$11.70M +15.4% |
-$13.83M -25.6% |
-$11.01M +20.6% |
-$13.88M -5.6% |
-$13.14M -31.6% |
-$9.98M +16.1% |
| Shares Outstanding | 33.01M +2.5% |
32.20M +3.4% |
31.15M +0.7% |
30.91M +2.9% |
30.05M +23.9% |
24.25M +19.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | April 30, 2023 | $210.0K | — | -59.1% |
| Revenue (ASC 606) | April 30, 2023 | $210.0K | — | -59.1% |
| Net Income | January 31, 2026 | -$2.56M | +19.4% | -13.6% |
| Diluted EPS | January 31, 2026 | -$0.08 | +20.0% | -14.3% |
| Total Assets | January 31, 2026 | $15.23M | -19.4% | -5.3% |
| Cash and Equivalents | January 31, 2026 | $1.55M | +46.9% | +24.4% |
| Stockholders Equity | January 31, 2026 | $15.08M | -15.5% | -0.6% |
| R&D Expense | January 31, 2026 | $1.10M | -29.0% | +4.5% |
| Operating Income | January 31, 2026 | -$2.72M | +19.8% | -11.5% |
| Shares Outstanding | January 31, 2026 | 33.46M | +3.9% | +1.4% |
- Anixa Biosciences Inc reported Total Revenue of $210.0 thousand for fiscal year 2023.
- Anixa Biosciences Inc showed a decrease of -59.0% in Total Revenue compared to the prior fiscal year.
- Anixa Biosciences Inc reported Revenue (ASC 606) of $210.0 thousand for fiscal year 2023.
- Anixa Biosciences Inc showed a decrease of -59.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Anixa Biosciences Inc reported Net Income of -$10.93 million for fiscal year 2025.
- Anixa Biosciences Inc showed an increase of +13.0% in Net Income compared to the prior fiscal year.
- Anixa Biosciences Inc reported Diluted EPS of $0.34 per share (loss) for fiscal year 2025.
- Anixa Biosciences Inc showed an increase of +12.8% in Diluted EPS compared to the prior fiscal year.
- Anixa Biosciences Inc reported Total Assets of $16.08 million for fiscal year 2025.
- Anixa Biosciences Inc showed a decrease of -25.5% in Total Assets compared to the prior fiscal year.
- Anixa Biosciences Inc reported Cash and Equivalents of $1.24 million for fiscal year 2025.
- Anixa Biosciences Inc showed a decrease of -2.1% in Cash and Equivalents compared to the prior fiscal year.
- Anixa Biosciences Inc reported Stockholders Equity of $15.16 million for fiscal year 2025.
- Anixa Biosciences Inc showed a decrease of -24.2% in Stockholders Equity compared to the prior fiscal year.
- Anixa Biosciences Inc reported R&D Expense of $5.07 million for fiscal year 2025.
- Anixa Biosciences Inc showed a decrease of -20.7% in R&D Expense compared to the prior fiscal year.
- Anixa Biosciences Inc reported Operating Income of -$11.70 million for fiscal year 2025.
- Anixa Biosciences Inc showed an increase of +15.4% in Operating Income compared to the prior fiscal year.
- Anixa Biosciences Inc reported Shares Outstanding of 33.01 million shares for fiscal year 2025.
- Anixa Biosciences Inc showed an increase of +2.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: